Nidan Laboratories and Healthcare Limited

As of March 31, 2025, Nidan Laboratories and Healthcare Limited carries a market capitalization of 230.05M, placing it among publicly traded companies globally. Its enterprise value stands at 322.15M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2025, Nidan Laboratories and Healthcare Limited has 13.90M shares outstanding.

These figures are as of March 31, 2025.

As of March 31, 2025, Nidan Laboratories and Healthcare Limited maintains a current ratio of 1.10, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2025.

As of the close on October 21, 2026, Nidan Laboratories and Healthcare Limited's stock has declined approximately 31.62% over the past 52 weeks. The 50-day moving average sits at 13.37, while the 200-day moving average is 15.20.

As of March 31, 2025, Nidan Laboratories and Healthcare Limited holds 18.99M in cash and equivalents against 111.10M in total debt, resulting in a net debt position of 92.11M. Total book value stands at 681.83M, with working capital of 10.06M providing operational flexibility.